Arch Venture Partners

The new company hopes to turn recombinant adeno-associated virus-based gene editing, which has minimal off-target effects, into new therapies.

The new firm will be based in the Boston area and is co-founded by MD Anderson Professor Raghu Kalluri and Broad Institute Director Eric Lander.

Leroy Hood called the bill short-sighted and said that over the long-term it could potentially reduce the attractiveness of starting up companies in the Seattle area.

The newly formed Decode Genetics Ehf will continue all of Decode's human genetics operations and brand products and services. Meantime, the publicly traded entity known as Decode Genetics expects to be liquidated.

Saga Investments has financial backing from Arch Venture Partners and Polaris Venture Partners, both of which had previously invested in Decode.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.